The effect of crocetin supplementation on markers of atherogenic risk in patients with coronary artery disease: a pilot, randomized, double-blind, placebo-controlled clinical trial
| Autor: | Mohammad Asghari Jafarabadi, S. Zahra Bathaie, Alireza Ostadrahimi, Saeed Abedimanesh, Mohammad Reza Sadeghi |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Male
0301 basic medicine medicine.medical_specialty Endothelium Homocysteine Crocetin Coronary Disease Pilot Projects Placebo Peripheral blood mononuclear cell 03 medical and health sciences chemistry.chemical_compound High-density lipoprotein Double-Blind Method Risk Factors Internal medicine Humans Medicine Vitamin A 030109 nutrition & dietetics business.industry General Medicine Middle Aged Atherosclerosis Carotenoids 030104 developmental biology medicine.anatomical_structure Endocrinology Gene Expression Regulation chemistry Dietary Supplements Female Animal studies business Biomarkers Food Science Lipoprotein |
| Zdroj: | Food & Function. 10:7461-7475 |
| ISSN: | 2042-650X 2042-6496 |
| DOI: | 10.1039/c9fo01166h |
| Popis: | Background and purpose: Molecular mechanisms of atherogenesis are considered to be emerging therapeutic targets for atherosclerosis prevention. Cell and animal studies have shown that crocetin can decelerate atherogenesis. However, the anti-atherogenic properties of crocetin in humans are still ambiguous. Methods and results: Fifty clinically diagnosed CAD patients were randomly divided into two parallel groups, crocetin and placebo, who received one capsule of crocetin (10 mg) and placebo per day, respectively, for two months. Serum circulating homocysteine (Hcy) [−1.09 (−1.64 to −0.54) μM, P = 0.001], heart-type fatty acid binding protein (h-FABP) [−2.07 (−2.72 to −1.43) ng mL−1, P = 0.001], intercellular adhesion molecule 1 [−14.92 (−21.92 to −7.92) ng mL−1, P = 0.001], vascular cell adhesion molecule 1 [−18.61 (−29.73 to −7.49) ng mL−1, P = 0.002], and monocyte chemoattractant protein 1 [−4.67 (−6.50 to −2.83) pg mL−1, P = 0.001] decreased significantly after the trial in the crocetin group, while high-density lipoprotein (HDL) significantly increased [+4.21 (0.68 to 7.73) mg mL−1, P = 0.021]. Also, systolic [−0.21 (−0.32 to −0.10) mmHg, P = 0.001] and diastolic [−0.20 (−0.34 to −0.07) mmHg, P = 0.004] blood pressures decreased significantly in the crocetin group. Nevertheless, clinically significant percentage changes were only observed in Hcy (−15.25 ± 3.15, μM), HDL (−10.70 ± 5.06, mg dL−1), and h-FABP (−21.10 ± 3.09, ng mL−1) in the crocetin group. Furthermore, the relative increase in the gene expressions of sirtuin1 and AMP-activated protein kinase and a decrease in the lectin-type oxidized LDL receptor 1 and nuclear factor-kappa B expression in isolated peripheral blood mononuclear cells in the crocetin group were significant at the end of the trial in comparison with the placebo. Conclusion: As the first human study, we showed the ability of crocetin to alter the expression of atherogenic genes and endothelial cell adhesion molecules in CAD patients. It appears that crocetin could be considered as a promising anti-atherogenic candidate for future studies. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|